Test Price
2,800 AED✅ Home Collection Available
DYX1C1 Gene Primary Ciliary Dyskinesia Type 25 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity via ISO-Accredited Cold-Chain Processing
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection
Telephonic Post-Test Result Interpretation by Clinical Experts
Direct Billing Verification via WhatsApp +971 54 548 8731
Accuracy: 99.9% Diagnostic Sensitivity via ISO-Accredited Cold-Chain Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection.
Clinical Guidance: Telephonic Post-Test Result Interpretation by Clinical Experts.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The DYX1C1 gene test detects pathogenic variants causing Primary Ciliary Dyskinesia Type 25 (PCD25), a rare genetic disorder marked by chronic respiratory infections, infertility, and laterality defects. This comprehensive NGS assay provides definitive molecular diagnosis, guiding personalized treatment and family planning.
| Feature | Our Test (DYX1C1 NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99% analytical sensitivity & specificity; full gene coverage | Limited to known hotspots, lower variant detection |
| Method | Next-Generation Sequencing (NGS) with bioinformatic validation | Capillary electrophoresis; may miss copy number variations |
| Turnaround | 3–4 weeks | 4–6 weeks |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics (DHA 9294403), I emphasize that a positive DYX1C1 result must be correlated with full clinical phenotype and family history. Early molecular diagnosis allows proactive management of respiratory complications and fertility counseling.”
“This test is a powerful guide, but it never replaces comprehensive clinical evaluation. Please share your report with your treating ENT and pulmonologist.”
⚠️ Important Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Genetic results do not alter acute treatment plans without clinical review.
Exclusion Criteria & Urgent Red Flags
- Active severe systemic infection or fever >38.5°C – test should be deferred.
- Recent blood transfusion (within 2 weeks) – may interfere with DNA purity.
- Pregnant minors (<18 years) without court-appointed guardian consent per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Seek ER if after sample collection you experience: sudden breathlessness, chest pain, cyanosis, or heavy uncontrolled bleeding.
Patient FAQ & Clinical Guidance
1. What does the DYX1C1 genetic test detect?
Snippet: The DYX1C1 NGS finds mutations linked to primary ciliary dyskinesia type 25 for precise clinical diagnosis.
It sequences the entire coding region of the DYX1C1 gene, identifying missense, nonsense, splicing variants, and small deletions. A positive result confirms the molecular basis of PCD25, enabling targeted screening of family members and early intervention with airway clearance therapies.
2. What sample types are accepted?
Snippet: Options: blood, extracted DNA, or single blood drop on FTA card; VIP mobile phlebotomy home collection available daily 8 AM–11 PM.
We accept whole blood collected in EDTA tubes, previously extracted DNA (concentration >20 ng/µL), or a simple dried blood spot on an FTA card. A DHA-licensed phlebotomist arrives equipped with validated cold-chain material for home collection.
3. How soon will I receive my results?
Snippet: Results ready in 3 to 4 weeks, with telephonic clinical guidance for your doctor's interpretation.
The complex NGS workflow—library preparation, sequencing, variant calling, and Sanger confirmation—requires 3–4 weeks. A board-certified geneticist reviews every report. On delivery, we offer a complimentary telephonic session to discuss findings and next steps with your referring physician.
UAE Regulatory & Data Privacy Adherence
This test is fully compliant with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring strict confidentiality of genetic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing secure digital health records.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – safeguarding patient consent and clinical safety.
ISO 9001:2015 Certified (INT/EGQ/2509DA/3139). All genetic information is encrypted and processed under DHA oversight.
Clinical & Logistical Metadata
| Test Name | DYX1C1 Gene Primary Ciliary Dyskinesia Type 25 Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, dried blood spot (FTA card) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM–11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | Q34.8, Z15.01, Z82.79 |
| LOINC Code | 93385-3 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians